Cargando…
Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities
BACKGROUND: Epidermal growth factor receptor inhibitors (EGFRI) produce various dermatologic side effects in the majority of patients, and guidelines are crucial for the prevention and treatment of these untoward events. The purpose of this panel was to develop evidence-based recommendations for EGF...
Autores principales: | Lacouture, Mario E., Anadkat, Milan J., Bensadoun, René-Jean, Bryce, Jane, Chan, Alexandre, Epstein, Joel B., Eaby-Sandy, Beth, Murphy, Barbara A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3128700/ https://www.ncbi.nlm.nih.gov/pubmed/21630130 http://dx.doi.org/10.1007/s00520-011-1197-6 |
Ejemplares similares
-
Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review
por: Lacouture, Mario E., et al.
Publicado: (2017) -
Dermatologic Toxicities in Epidermal Growth Factor Receptor and Multikinase Inhibitors
por: Eaby-Sandy, Beth, et al.
Publicado: (2012) -
Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines
por: Lacouture, Mario E., et al.
Publicado: (2020) -
Management of Dermatologic Toxicities Associated With Targeted Therapy
por: Lacouture, Mario E.
Publicado: (2016) -
Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy
por: Lacouture, Mario E., et al.
Publicado: (2021)